Wuhan Hvsen Valuation
| 300871 Stock | 11.01 0.60 5.17% |
At this time, the company appears to be overvalued. Wuhan Hvsen Biotechnology maintains a prevalent Real Value of USD8.91 per share. The last-minute price of the company is USD11.01. Our model calculates the value of Wuhan Hvsen Biotechnology from examining the company fundamentals such as Profit Margin of (0.04) %, current valuation of 2.39 B, and Return On Asset of -0.0029 as well as analyzing its technical indicators and probability of bankruptcy.
Price Book 1.3702 | Enterprise Value 2.4 B | Enterprise Value Ebitda 19.8513 | Price Sales 1.6445 | Enterprise Value Revenue 2.1334 |
Overvalued
Today
Please note that Wuhan Hvsen's price fluctuation is somewhat reliable at this time. Calculation of the real value of Wuhan Hvsen Biotechnology is based on 3 months time horizon. Increasing Wuhan Hvsen's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Wuhan Hvsen is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Wuhan Stock. However, Wuhan Hvsen's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.01 | Real 8.91 | Hype 10.98 | Naive 10.79 |
The real value of Wuhan Stock, also known as its intrinsic value, is the underlying worth of Wuhan Hvsen Biotechnology Company, which is reflected in its stock price. It is based on Wuhan Hvsen's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Wuhan Hvsen's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Wuhan Hvsen Biotechnology helps investors to forecast how Wuhan stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Wuhan Hvsen more accurately as focusing exclusively on Wuhan Hvsen's fundamentals will not take into account other important factors: Wuhan Hvsen Cash |
|
Wuhan Hvsen Total Value Analysis
Wuhan Hvsen Biotechnology is presently forecasted to have takeover price of 2.39 B with market capitalization of 1.84 B, debt of 240.32 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Wuhan Hvsen fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.39 B | 1.84 B | 240.32 M |
Wuhan Hvsen Investor Information
About 61.0% of the company shares are owned by insiders or employees . The company has Price-to-Book (P/B) ratio of 1.37. In the past many companies with similar price-to-book ratios have beat the market. Wuhan Hvsen Biotechnology recorded a loss per share of 0.28. The entity last dividend was issued on the 29th of May 2024. The firm had 1.5:1 split on the 10th of May 2021. Based on the analysis of Wuhan Hvsen's profitability, liquidity, and operating efficiency, Wuhan Hvsen Biotechnology is performing exceptionally good at this time. It has a great odds to report excellent financial results in December.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 90.8 M | 92.9 M |
|
| |||||
| Operating Income | 82.1 M | 41.9 M |
|
|
Wuhan Hvsen Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Wuhan suggests not a very effective usage of assets in November.Wuhan Hvsen Ownership Allocation
Wuhan Hvsen Biotechnology retains a total of 165.77 Million outstanding shares. Wuhan Hvsen Biotechnology maintains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 60.51 (%) of Wuhan Hvsen Biotechnology outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Wuhan Hvsen Profitability Analysis
The company reported the revenue of 1.02 B. Net Income was 16.78 M with profit before overhead, payroll, taxes, and interest of 222.75 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Wuhan Hvsen's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Wuhan Hvsen and how it compares across the competition.
About Wuhan Hvsen Valuation
The stock valuation mechanism determines Wuhan Hvsen's current worth on a weekly basis. Our valuation model uses a comparative analysis of Wuhan Hvsen. We calculate exposure to Wuhan Hvsen's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Wuhan Hvsen's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 213.3 M | 243.2 M |
Wuhan Hvsen Quarterly Retained Earnings |
|
Complementary Tools for Wuhan Stock analysis
When running Wuhan Hvsen's price analysis, check to measure Wuhan Hvsen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Wuhan Hvsen is operating at the current time. Most of Wuhan Hvsen's value examination focuses on studying past and present price action to predict the probability of Wuhan Hvsen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Wuhan Hvsen's price. Additionally, you may evaluate how the addition of Wuhan Hvsen to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |